Mark H. Eckman, MD, and Steven A. Lubitz, MD, MPH, received the first Atrial Fibrillation (AFib) Quality Improvement Innovation Grants. Both were recognized at Friday night’s Award Ceremony.
Boehringer Ingelheim Pharmaceuticals, Inc., worked with the Heart Rhythm Society in the call for grant applications to support innovation and advancement in AFib and stroke prevention research aimed at addressing National Quality Improvement (QI) priorities via demonstration projects/research.
Boehringer Ingelheim provided $500,000 to support multiple grants to eligible applicants for proposals that aim to affect the behaviors and performance of patients, providers, and/or systems that when combined with existing standards and approaches to care may enhance patient outcomes.
Dr. Eckman, with the University of Cincinnati, Cincinnati, Ohio, submitted Shared Decision-Making Tool for Thromboprophylaxis in Atrial Fibrillation.
Dr. Lubitz, with Massachusetts General Hospital, Boston, submitted Automated Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation.
HRS received applications from U.S.-based healthcare providers, research scientists, and centers for excellence focused on QI demonstration projects/research. Six finalists presented their proposals at this year’s Scientific Sessions, and Dr. Eckman and Lubits will present their findings at Heart Rhythm 2017 in Chicago.
For more information, visit www.hrsonline.org/AFibGrant.